Oramed Pharmaceuticals
(NASDAQ) ORMP
Oramed Pharmaceuticals Financials at a Glance
Market Cap
$188.26M
Revenue (TTM)
$0.00
Net Income (TTM)
$110.00M
EPS (TTM)
$2.58
P/E Ratio
1.78
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$4.58
Volume
36
Open
$4.73
Price
$4.58
Volume
36
Open
$4.73
Previous Close
$4.60
Daily Range
$4.49 - $4.83
52-Week Range
$1.98 - $5.19
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$4.58
Volume
36
Open
$4.73
Previous Close
$4.60
Daily Range
$4.49 - $4.83
52-Week Range
$1.98 - $5.19
Estimated Earnings Date
Aug 13, 2026
ORMP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Oramed Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
13
CEO
Nadav Kidron, MBA
Website
www.oramed.comHeadquarters
New York City, NY 10036, US
ORMP Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
55.29%
Return on Capital
-7.52%
Return on Assets
40.92%
Earnings Yield
56.18%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$188.26M
Shares Outstanding
40.93M
Volume
36
Avg. Volume
282.01K
Financials (TTM)
Gross Profit
-$121.00K
Operating Income
-$14.25M
EBITDA
$78.84M
Operating Cash Flow
-$8.94M
Capital Expenditure
$192.68K
Free Cash Flow
-$8.74M
Cash & ST Invst.
$65.84M
Total Debt
$761.00K
Oramed Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$30.00K
-330.8%
Gross Margin
0.00%
N/A
Market Cap
$188.26M
N/A
Market Cap/Employee
$14.48M
N/A
Employees
13
N/A
Net Income
$38.31M
+601.3%
EBITDA
-$3.63M
+18.8%
Quarterly Fundamentals
Total Cash
$65.84M
-49.6%
Total Debt
$761.00K
+152.8%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$493.00K
+310.8%
Short Term Debt
$268.00K
+48.1%
Return on Assets
40.92%
N/A
Return on Invested Capital
-5.52%
N/A
Free Cash Flow
-$2.92M
+17.1%
Operating Cash Flow
-$2.92M
+17.2%